Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study.
head and neck squamous cell carcinoma
immune-related toxicities
immunotherapy
nivolumab
palliative
real-world data
recurrent/metastatic HNSCC
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Mar 2021
19 Mar 2021
Historique:
received:
08
02
2021
revised:
09
03
2021
accepted:
15
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Nivolumab is an anti-PD-1 monoclonal antibody currently used as immunotherapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of disease progression after platinum-based chemotherapy. This study evaluates real-world safety and treatment outcomes of non-trial nivolumab use. A retrospective multicenter cohort study of patients with recurrent/metastatic HNSCC treated with nivolumab between January 2017 and March 2020 was performed. Overall, 123 patients were included. The median age was 64 years, the majority of patients were male (80.5%) and had a smoking history (69.9%). Primary outcomes included overall response rate (ORR) of 19.3%, median progression-free survival (PFS) of 3.9 months, 1-year PFS rate of 16.8%, a median overall survival (OS) of 6.5 months and 1-year OS rate of 28.6%. These results are comparable to the CHECKMATE-141 study. Of 27 patients who had PD-L1 status tested, positive PD-L1 status did not significantly affect PFS (
Identifiants
pubmed: 33808781
pii: cancers13061413
doi: 10.3390/cancers13061413
pmc: PMC8003537
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Mayo Clin Proc. 2008 Apr;83(4):489-501
pubmed: 18380996
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
J Immunother Cancer. 2019 Nov 15;7(1):306
pubmed: 31730012
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Acta Otolaryngol. 2019 Oct;139(10):918-925
pubmed: 31460818
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Oral Oncol. 2020 Feb;101:104525
pubmed: 31863963
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
Ann Oncol. 2010 Oct;21 Suppl 7:vii252-61
pubmed: 20943624
Cancers (Basel). 2019 Sep 06;11(9):
pubmed: 31500103
Acta Otorhinolaryngol Ital. 2020 Apr;40(SUPPL. 1):S1-S86
pubmed: 32469009
Eur J Cancer. 2018 Sep;101:69-76
pubmed: 30031168
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494